Development of a mutant aerosolized ACE2 that neutralizes SARS-CoV-2 in vivo

The rapid evolution of SARS-CoV-2 variants highlights the need for new therapies to prevent disease spread. SARS-CoV-2, like SARS-CoV-1, uses the human cell surface protein angiotensin-converting enzyme 2 (ACE2) as its native receptor. Here, we design and characterize a mutant ACE2 that enables rapi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kober, Daniel L., Caballero Van Dyke, Marley C., Eitson, Jennifer L., Boys, Ian N., McDougal, Matthew B., Rosenbaum, Daniel M., Schoggins, John W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557691/
https://www.ncbi.nlm.nih.gov/pubmed/37808801
http://dx.doi.org/10.1101/2023.09.26.559550

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557691/
https://www.ncbi.nlm.nih.gov/pubmed/37808801
http://dx.doi.org/10.1101/2023.09.26.559550

Ejemplares similares